PLoS ONE (Jan 2013)

Potent inhibition of Hendra virus infection via RNA interference and poly I:C immune activation.

  • Jana L McCaskill,
  • Glenn A Marsh,
  • Paul Monaghan,
  • Lin-Fa Wang,
  • Timothy Doran,
  • Nigel A J McMillan

DOI
https://doi.org/10.1371/journal.pone.0064360
Journal volume & issue
Vol. 8, no. 5
p. e64360

Abstract

Read online

Hendra virus (HeV) is a highly pathogenic zoonotic paramyxovirus that causes fatal disease in a wide range of species, including humans. HeV was first described in Australia in 1994, and has continued to re-emerge with increasing frequency. HeV is of significant concern to human health due to its high mortality rate, increasing emergence, absence of vaccines and limited post exposure therapies. Here we investigate the use of RNA interference (RNAi) based therapeutics targeting HeV in conjunction with the TLR3 agonist Poly I:C and show that they are potent inhibitors of HeV infection in vitro. We found that short interfering RNAs (siRNAs) targeting the abundantly expressed N, P and M genes of HeV caused over 95% reduction of HeV virus titre, protein and mRNA. Furthermore, we found that the combination of HeV targeting siRNA and Poly I:C had an additive effect in suppressing HeV infection. Our results demonstrate for the first time that RNAi and type I interferon stimulation are effective inhibitors of HeV replication in vitro and may provide an effective therapy for this highly lethal, zoonotic pathogen.